NEW YORK, NY / ACCESSWIRE / March 9, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
FENC Shareholders Click Here: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=24494&wire=1
BFLY Shareholders Click Here: https://www.zlk.com/pslra-1/butterfly-network-inc-loss-submission-form?prid=24494&wire=1
CRNC Shareholders Click Here: https://www.zlk.com/pslra-1/cerence-inc-loss-submission-form?prid=24494&wire=1
* ADDITIONAL INFORMATION BELOW *
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
FENC Lawsuit on behalf of: investors who purchased May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline: April 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=24494&wire=1
According to the filed complaint, during the class period, Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Butterfly Network, Inc. f/k/a Longview Acquisition Corp. (NYSE:BFLY)
This lawsuit is one behalf of: (a) all persons or entities that purchased or otherwise acquired Butterfly securities between February 16, 2021 and November 15, 2021, both dates inclusive and/or (b) all holders of Butterfly common stock as of the record date for the special meeting of shareholders held on February 12, 2021 to consider approval of the merger between Longview Acquisition Corp. and Butterfly.
Lead Plaintiff Deadline: April 18, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/butterfly-network-inc-loss-submission-form?prid=24494&wire=1
According to the filed complaint, (i) Butterfly had overstated its post-merger business and financial prospects; (ii) notwithstanding the ongoing COVID-19 pandemic, Butterfly’s financial projections failed to take into account the pandemic’s broad consequences, which included healthcare logistical challenges, and medical personnel fatigue; (iii) accordingly, Butterfly’s gross margin levels and revenue projections were less sustainable than the Company had represented; (iv) all the foregoing was reasonably likely to have a material negative impact on Butterfly’s business and financial condition; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Cerence Inc. (NASDAQ:CRNC)
CRNC Lawsuit on behalf of: investors who purchased February 8, 2021 – February 4, 2022
Lead Plaintiff Deadline : April 26, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cerence-inc-loss-submission-form?prid=24494&wire=1
According to the filed complaint, during the class period, Cerence Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the global semiconductor shortage had a materially negative impact on demand for Cerence’s software licenses; (2) defendants masked the impact of the semiconductor shortage on demand for the Company’s software licenses by pulling forward sales; and (3) as a result of the above, defendants’ statements about Cerence’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/692371/CLASS-ACTION-UPDATE-for-FENC-BFLY-and-CRNC-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders